Tumor genotype determines susceptibility to oncolytic herpes simplex virus mutants: strategies for clinical application.
about
Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade gliomaUV-inactivated HSV-1 potently activates NK cell killing of leukemic cells.Rethinking herpes simplex virus: the way to oncolytic agents.Dual silencing of Bcl-2 and Survivin by HSV-1 vector shows better antitumor efficacy in higher PKR phosphorylation tumor cells in vitro and in vivo.Targeting human glioma cells using HSV-1 amplicon peptide display vector.
P2860
Tumor genotype determines susceptibility to oncolytic herpes simplex virus mutants: strategies for clinical application.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Tumor genotype determines susc ...... gies for clinical application.
@en
type
label
Tumor genotype determines susc ...... gies for clinical application.
@en
prefLabel
Tumor genotype determines susc ...... gies for clinical application.
@en
P2093
P2860
P356
P1433
P1476
Tumor genotype determines susc ...... gies for clinical application.
@en
P2093
Kerrington D Smith
Michael Y Shao
Mitchell C Posner
P2860
P304
P356
10.2217/14796694.3.5.545
P407
P577
2007-10-01T00:00:00Z